Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have previously been diagnosed with multiple myeloma, confirmed using standard international diagnostic criteria.
- People whose multiple myeloma is still detectable through specific blood or urine tests measuring abnormal proteins produced by the cancer.
- (Part 1 of the trial) People who have received between 2 and 4 previous treatment courses for multiple myeloma, including at least one drug from each of two specific treatment families: immunomodulatory drugs and proteasome inhibitors.
- (Part 2 of the trial) People who have received between 1 and 3 previous treatment courses for multiple myeloma, including at least one drug from each of those same two treatment families.
- People with a good general health and activity level, rated 0 or 1 on a standard medical scale (confirm with trial site).
- People whose side effects from any previous treatments have fully resolved or reduced to a mild level before joining the trial.
Who may not be able to join:
- People who have certain related but distinct blood or plasma cell conditions, including plasma cell leukemia, smoldering multiple myeloma, Waldenström's macroglobulinemia, amyloidosis, or POEMS syndrome.
- People with significant heart or blood vessel problems.
- People who have had a stem cell transplant within the 12 weeks before enrolling, or who are experiencing active graft versus host disease (a complication that can follow a transplant).
- People who currently have an active, uncontrolled bacterial, fungal, or viral infection.
- People who have had another type of cancer within the past 3 years, unless it was a successfully treated minor skin cancer or a non-invasive cancer confined to its original site.
- People who have previously been treated with therapies that target a protein called BCMA, or therapies that redirect a type of immune cell called CD3.
- People who have previously received the specific drugs iberdomide (CC-220) or mezigdomide.
- People who have taken certain medications known to strongly interfere with how the body processes drugs (strong CYP3A4/5 inhibitors or inducers) within 2 weeks before starting the trial or during the trial.
- People who have taken part in another experimental drug trial within 30 days before the first dose in this study.
- People who are unable or unwilling to follow the trial's required preventive treatment for blood clots.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1: Number of participants with dose limiting toxicity (DLT); Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.